催化剂制药公司将在2026年底之前回购2亿美元的股票, 提高投资者的信心. Catalyst Pharma to repurchase $200M in shares by end of 2026, boosting investor confidence.

催化药品公司于2025年10月1日宣布了2亿美元份额回购方案,以在2026年12月31日前以现金储备供资,回购共同股票。 Catalyst Pharmaceuticals, Inc. announced on October 1, 2025, a $200 million share repurchase program to buy back its common stock by December 31, 2026, funded by its cash reserves. 此举旨在将价值回报给股东并表明对公司财政实力的信心,其结果是现金头寸强劲,业务始终如一。 The move, intended to return value to shareholders and signal confidence in the company’s financial strength, follows strong cash positions and consistent operations. 股价在新闻上上升了5.38%,反映出投资者的乐观态度。 The stock rose 5.38% on the news, reflecting investor optimism. 回购可能在开放市场或私人交易中发生,视条件而定,但得不到保证。 Repurchases may occur in open markets or private deals, depending on conditions, but are not guaranteed.